BioCentury
ARTICLE | Financial News

Emergent lands BARDA contract for new anthrax vaccine

September 30, 2016 7:00 AM UTC

Emergent BioSolutions Inc. (NYSE:EBS) gained $3.77 (14%) to $31.53 on Friday after it said it signed a contract with HHS's Biomedical Advanced Research and Development Authority worth up to $1.6 billion to develop NuThrax ( AV7909). The company also said the CDC exercised an option to purchase all the remaining doses of its BioThrax vaccine under a 2011 contract.

Emergent said the new contract includes about $200 million over five years to develop the vaccine and to supply an initial two million doses for the U.S. Strategic National Stockpile. NuThrax is in Phase III testing, and Emergent said it believes FDA could approve the vaccine for emergency use as soon as 2018. ...